Although the clinical development of immune checkpoint inhibitors (ICIs) therapy has
ushered in a new era of anti-tumor therapy, with sustained responses and significant survival …

Over the last decade, based on the extensive development of preclinical animal studies and
clinical trials, the efficacy, and mechanisms of immunotherapy have been fully explored. …

Background γδ T cells are a distinct subgroup of T cells containing T cell receptors (TCRs) γ
and TCR δ chains with diverse structural and functional heterogeneity. As a bridge between …

Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV)
infection is the main causative factor. Patients with hepatocellular carcinoma have a poor …

Background Immunotherapy combined with chemotherapy has been shown to be efficacious
as treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) without …

Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has
changed the approach to first-line treatment in patients with extensive-stage small cell lung …

Background A substantial proportion of patients with unresectable stage III non-small-cell
lung cancer (NSCLC) cannot either tolerate or access concurrent chemoradiotherapy, so …

Background PD-1 inhibitor plus chemotherapy had been shown to be an effective first-line
treatment for patients with metastatic non-small-cell lung cancer (NSCLC). However, there …

Introduction The standard chemotherapy for squamous NSCLC (sqNSCLC) includes platinum
plus gemcitabine. Sintilimab, an anti–programmed cell death protein 1 antibody, plus …

Background Friend leukemia virus integration 1 (FLI1), an ETS transcription factor family
member, acts as an oncogenic driver in hematological malignancies and promotes tumor …